Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson's disease.
Identifieur interne : 000160 ( PubMed/Curation ); précédent : 000159; suivant : 000161Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson's disease.
Auteurs : James. Sheffield [États-Unis] ; Joseph JankovicSource :
- Expert review of neurotherapeutics ; 2007.
English descriptors
- KwdEn :
- Antidepressive Agents, Second-Generation (administration & dosage), Botulinum Toxins (administration & dosage), Clinical Trials as Topic (trends), Dose-Response Relationship, Drug, Dystonia (drug therapy), Dystonia (etiology), Humans, Parkinson Disease (complications), Parkinson Disease (drug therapy), Practice Patterns, Physicians' (trends), Sialorrhea (drug therapy), Sialorrhea (etiology), Treatment Outcome, Tremor (drug therapy), Tremor (etiology).
- MESH :
- chemical , administration & dosage : Antidepressive Agents, Second-Generation, Botulinum Toxins.
- complications : Parkinson Disease.
- drug therapy : Dystonia, Parkinson Disease, Sialorrhea, Tremor.
- etiology : Dystonia, Sialorrhea, Tremor.
- trends : Clinical Trials as Topic, Practice Patterns, Physicians'.
- Dose-Response Relationship, Drug, Humans, Treatment Outcome.
Abstract
Botulinum toxins are an effective treatment modality for a growing number of neurologic conditions. Although there has been varied interest and success in their use, they have been studied for a variety of conditions associated with Parkinson's disease. Conditions reviewed in this paper include hand and jaw tremor, dystonia, blepharospasm and apraxia of eyelid opening, bruxism, camptocormia, freezing of gait, sialorrhea and constipation. We will make comments when applicable on our unique experience with botulinum toxin in these conditions. Other conditions associated with Parkinson's disease, which will not be reviewed here, but may benefit from botulinum toxin treatment include anterocollis (also known as dropped head syndrome), hyperhidrosis, seborrhea and overactive bladder.
DOI: 10.1586/14737175.7.6.637
PubMed: 17563247
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000160
Links to Exploration step
pubmed:17563247Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson's disease.</title><author><name sortKey="Sheffield, James K" sort="Sheffield, James K" uniqKey="Sheffield J" first="James" last="Sheffield">James. Sheffield</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Baylor College of Medicine, Parkinson's Disease Center & Movement Disorders Clinic, 6550 Fannin, Suite 1801, Houston, TX 77030, USA. jksheffi@bcm.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Baylor College of Medicine, Parkinson's Disease Center & Movement Disorders Clinic, 6550 Fannin, Suite 1801, Houston, TX 77030</wicri:regionArea></affiliation></author><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2007">2007</date><idno type="doi">10.1586/14737175.7.6.637</idno><idno type="RBID">pubmed:17563247</idno><idno type="pmid">17563247</idno><idno type="wicri:Area/PubMed/Corpus">000160</idno><idno type="wicri:Area/PubMed/Curation">000160</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson's disease.</title><author><name sortKey="Sheffield, James K" sort="Sheffield, James K" uniqKey="Sheffield J" first="James" last="Sheffield">James. Sheffield</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Baylor College of Medicine, Parkinson's Disease Center & Movement Disorders Clinic, 6550 Fannin, Suite 1801, Houston, TX 77030, USA. jksheffi@bcm.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Baylor College of Medicine, Parkinson's Disease Center & Movement Disorders Clinic, 6550 Fannin, Suite 1801, Houston, TX 77030</wicri:regionArea></affiliation></author><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name></author></analytic><series><title level="j">Expert review of neurotherapeutics</title><idno type="e-ISSN">1744-8360</idno><imprint><date when="2007" type="published">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antidepressive Agents, Second-Generation (administration & dosage)</term><term>Botulinum Toxins (administration & dosage)</term><term>Clinical Trials as Topic (trends)</term><term>Dose-Response Relationship, Drug</term><term>Dystonia (drug therapy)</term><term>Dystonia (etiology)</term><term>Humans</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term><term>Practice Patterns, Physicians' (trends)</term><term>Sialorrhea (drug therapy)</term><term>Sialorrhea (etiology)</term><term>Treatment Outcome</term><term>Tremor (drug therapy)</term><term>Tremor (etiology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antidepressive Agents, Second-Generation</term><term>Botulinum Toxins</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dystonia</term><term>Parkinson Disease</term><term>Sialorrhea</term><term>Tremor</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dystonia</term><term>Sialorrhea</term><term>Tremor</term></keywords><keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Clinical Trials as Topic</term><term>Practice Patterns, Physicians'</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Dose-Response Relationship, Drug</term><term>Humans</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Botulinum toxins are an effective treatment modality for a growing number of neurologic conditions. Although there has been varied interest and success in their use, they have been studied for a variety of conditions associated with Parkinson's disease. Conditions reviewed in this paper include hand and jaw tremor, dystonia, blepharospasm and apraxia of eyelid opening, bruxism, camptocormia, freezing of gait, sialorrhea and constipation. We will make comments when applicable on our unique experience with botulinum toxin in these conditions. Other conditions associated with Parkinson's disease, which will not be reviewed here, but may benefit from botulinum toxin treatment include anterocollis (also known as dropped head syndrome), hyperhidrosis, seborrhea and overactive bladder.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">17563247</PMID><DateCreated><Year>2007</Year><Month>06</Month><Day>12</Day></DateCreated><DateCompleted><Year>2007</Year><Month>07</Month><Day>03</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1744-8360</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><Issue>6</Issue><PubDate><Year>2007</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Expert review of neurotherapeutics</Title><ISOAbbreviation>Expert Rev Neurother</ISOAbbreviation></Journal><ArticleTitle>Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>637-47</MedlinePgn></Pagination><Abstract><AbstractText>Botulinum toxins are an effective treatment modality for a growing number of neurologic conditions. Although there has been varied interest and success in their use, they have been studied for a variety of conditions associated with Parkinson's disease. Conditions reviewed in this paper include hand and jaw tremor, dystonia, blepharospasm and apraxia of eyelid opening, bruxism, camptocormia, freezing of gait, sialorrhea and constipation. We will make comments when applicable on our unique experience with botulinum toxin in these conditions. Other conditions associated with Parkinson's disease, which will not be reviewed here, but may benefit from botulinum toxin treatment include anterocollis (also known as dropped head syndrome), hyperhidrosis, seborrhea and overactive bladder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sheffield</LastName><ForeName>James K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Department of Neurology, Baylor College of Medicine, Parkinson's Disease Center & Movement Disorders Clinic, 6550 Fannin, Suite 1801, Houston, TX 77030, USA. jksheffi@bcm.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jankovic</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Expert Rev Neurother</MedlineTA><NlmUniqueID>101129944</NlmUniqueID><ISSNLinking>1473-7175</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018687">Antidepressive Agents, Second-Generation</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.69</RegistryNumber><NameOfSubstance UI="D001905">Botulinum Toxins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018687">Antidepressive Agents, Second-Generation</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001905">Botulinum Toxins</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000008">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002986">Clinical Trials as Topic</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000639">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D004421">Dystonia</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010818">Practice Patterns, Physicians'</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000639">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012798">Sialorrhea</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014202">Tremor</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>107</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>6</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>7</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>6</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1586/14737175.7.6.637</ArticleId><ArticleId IdType="pubmed">17563247</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/JankovicV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000160 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000160 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= JankovicV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:17563247
|texte= Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:17563247" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a JankovicV1
| This area was generated with Dilib version V0.6.19. |  |